Drug intelligence / Profile preview

TXN10128 + paclitaxel

Development stage
Unknown
Lead developer
Txinno Bioscience
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

**TXN10128 + paclitaxel** is an investigational combination therapy being studied in adults with locally advanced or metastatic solid tumors that have relapsed or are refractory to standard treatment. TXN10128 is a small molecule inhibitor of ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1), designed to disrupt ENPP1-mediated pathways involved in tumor progression. Paclitaxel is a well-established microtubule-stabilizing chemotherapeutic agent that inhibits cell division, approved for multiple cancer indications. The combination is delivered as oral TXN10128 and intravenous paclitaxel, with a Phase 1 clinical trial currently recruiting to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity in solid tumors, including specific arms for breast cancer patients[1][2].

Other names
TXN10128 + paclitaxel
02

Targets

TUBB (Tubulin (alpha and beta subunits))ENPP1

Beyond the preview

Go deeper on TXN10128 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TXN10128 + paclitaxel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call